QUOTE AND NEWS
FierceBiotech  Aug 21  Comment 
Pharma giants AstraZeneca, Johnson & Johnson and Sanofi have teamed up with gene sequencing pioneer Illumina to create a single test that screen patients for a wealth of cancer-related gene variants, allowing drugmakers to identify the ideal...
StreetInsider.com  Aug 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Illumina+%28ILMN%29+Enters+Patnerships+for+Next-Gen+NGS-Based+Oncology+Test+System+%28SNY%29/9772762.html for the full story.
newratings.com  Aug 21  Comment 
LONDON (dpa-AFX) - Biotechnology company Illumina Inc. (ILMN) has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing or NGS-based oncology test system. The system would be used...
FiercePharma  Aug 20  Comment 
More than a couple of markets have been shaken up lately by new competition in oral form. And now, Sanofi's Genzyme is wondering if it can't make a splash of its own with Cerdelga, its newly approved pill for Gaucher disease.
MedPage Today  Aug 20  Comment 
(MedPage Today) -- The FDA has tentatively approved Eli Lilly's "biosimilar" insulin glargine (Basaglar), but it won't be on the market until the company resolves patent litigation with Sanofi.
Market Intelligence Center  Aug 20  Comment 
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Sanofi-Aventis (SNY) that includes 8.26% downside protection. Sell one contract of the Mar. '15...
StreetInsider.com  Aug 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi%27s+%28SNY%29+Genzyme+Receives+FDA+Approval+for+Cerdelga/9767767.html for the full story.
FiercePharma  Aug 19  Comment 
Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.
SeekingAlpha  Aug 19  Comment 
By Jason Napodano, CFA: On August 14, 2014, Aastrom Biosciences, Inc. (NASDAQ:ASTM) reported financial results for the second quarter of 2014. Results included one full quarter of operations for the company's recently acquired Cell Therapy and...
FierceBiotech  Aug 19  Comment 
Eli Lilly has won a "tentative" FDA approval for its knockoff of Sanofi's Lantus, but don't look for it at a pharmacy anytime soon. The insulin glargine injection--to be marketed as Basaglar eventually in the U.S.--faces an automatic 30-month stay...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki